Home > Boards > Stock Clubs > Technical Analysis > QualityStocks

QualityStocksNewsBreaks – Vivos Therapeutics Inc.’s Innovative System Leverages

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
QualityStocks Member Profile
 
Followed By 423
Posts 43,302
Boards Moderated 2
Alias Born 05/08/06
160x600 placeholder
Top Company News of the Day
The personal-computer maker said it intends to use net proceeds from the deal to pay down debt.
Dell Plans Spinoff of $52 Billion Stake in VMware -- Update
U.S. Vaccine Panel Opts Not to Vote on J&J Covid-19 Shot's Clot Risk -- Update
U.S. Vaccine Panel Opts Not to Vote on J&J Covid-19 Vaccine Clot Risk
Dell Plans Spinoff of $52 Billion Stake in VMware
Top Stories of the Day
Wells Fargo Earnings Jump as Economy Bounces Back -- 4th Update
Dow Pares Gains, S&P 500 Closes Lower -- Update
Dell Plans Spinoff for VMware Stake
Costco Raises Quarter Dividend to 79 Cents/Share
Wall Street Businesses Power Goldman, JPMorgan to Record Earnings -- Update
Bristol Myers Squibb Gets EU Approval for Renal Cell Carcinoma Treatment
Dow Pares Gains, S&P 500 Closes Lower
Thermo Fisher Nears Deal to Buy PPD for More Than $15 Billion -- Update
PPD Inc. Shares Up After WSJ Report Thermo Fisher Nearing Deal to Buy Co.
Thermo Fisher Nears Deal to Buy PPD for More Than $15 Billion
Central Bank Will Begin Reducing Bond Purchases 'Well Before' Raising Interest Rates, Powell Says -- 2nd Update
Wheat Higher on Midwest Cold Snap
J&J Covid-19 Vaccine Blood-Clot Cases Could Stir Vaccine Hesitancy - Update
U.S. Business Activity Picks Up Due to Stronger Consumer Spending - Fed's Beige Book -- Update
Central Bank Will Begin Reducing Bond Purchases 'Well Before' Raising Interest Rates, Powell Says -- Update
Dow Pares Gains, S&P 500 Declines
J&J Covid-19 Vaccine Blood-Clot Cases Could Stir Vaccine Hesitancy
U.S. Business Activity Picks Up Due to Stronger Consumer Spending - Fed's Beige Book
Air Products Acquires Remaining 50% of JV from China Energy Group Subsidiary
QualityStocks   Friday, 07/10/20 04:37:28 PM
Re: None
Post # of 26891 
QualityStocksNewsBreaks – Vivos Therapeutics Inc.’s Innovative System Leverages Multidisciplinary Protocol in OSA Treatment

Vivos Therapeutics’ proprietary Vivos System(R) leverages a multidisciplinary treatment protocol comprised of comfortable oral devices and other therapies as needed. Over the course of treatment, typically ranging from 18 to 24 months, most patients experience an increased and enhanced upper airway with the purpose of reducing tissue obstructions causing obstructive sleep apnea (“OSA”). A recent article discussing this reads, “Vivos Therapeutics Inc. offers a new and superior alternative for treating obstructive sleep apnea, and the company believes its technology represents the most important breakthrough in OSA treatment since Continuous Positive Airway Pressure (‘CPAP’), which involves the use of special face or nasal masks.”

To view the full article, visit http://ibn.fm/B1NW2

About Vivos Therapeutics Inc.

Vivos Therapeutics is an emerging global leader in the treatment of obstructive sleep apnea (“OSA”), a debilitating condition affecting nearly 1 billion people worldwide. Headquartered in Denver, Colorado, the company utilizes proprietary, groundbreaking technology; a proven, go-to-market strategy; and a powerful executive team dedicated to changing the face of health care by helping people of all ages properly breathe and sleep. At the core of Vivos’ mission to eradicate OSA is the Vivos System(R), a revolutionary clinical breakthrough in the treatment of sleep apnea caused by craniofacial anatomy development. The Vivos System multidisciplinary treatment protocol involves collaboration between physicians, specially trained dentists who have completed advanced training in craniofacial sleep medicine, and other ancillary health-care providers. In support of its growth strategy, Vivos has established FDA-approved and registered manufacturing facilities in the United States, Canada and Asia. For more information, visit the company’s website at www.VivosLife.com.

NOTE TO INVESTORS: The latest news and updates relating to Vivos Therapeutics are available in the company’s newsroom at http://ibn.fm/VVOS



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences